396 / 1778
• Significant heterogeneity among the trials
• It may be inappropriate to combine the trials
• Trials divided in two ways:
– Cycle interval (> 14 d Vs ≤ 14 d)
– Cisplatin dose intensity (< 25 Vs ≥ 25 mg/m2/wk)
Comparison 1
NACT followed by RT Vs RT